Business Case

Product development and commercialization support for an imaging biomarker in Alzheimer’s

Our client, a leading developer and manufacturer of ophthalmic diagnostic imaging systems, was exploring a new application of optical coherence tomography (OCT) and OCT-angiography along with Al-enabled image analysis to assess structural and functional changes in the retinas of people with, or at risk for, cognitive impairment and Alzheimer’s Disease.

LSC conducted a market analysis to define the prospective role and potential market opportunity for OCT/OCT-A in clinical research and ultimately as a diagnostic tool in assessing and monitoring dementia. Working with leading neurology, ophthalmology and neuro-ophthalmology key opinion leaders and research centers in the US and Europe, LSC developed and supported clinical and product development initiatives that resulted in accelerated scientific publications, clinical validation, and pharma partner engagement. The product shows promise as a low-cost, non-invasive, office-based diagnostic tool to support early therapeutic interventions.